Understand the source comparison
Is Mazdutide Safe Side Effects: Comparison Across Metabolic Peptides
Understanding mazdutide's safety profile requires context—how does it compare to related compounds targeting similar metabolic pathways? Mazdutide Dual GIP/GLP-1 agonist 42% at 6mg weekly dose (highest studied) 6.8% at 6mg (Phase 2 data) Dual receptor activati
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding mazdutide's safety profile requires context—how does it compare to related compounds targeting similar metabolic pathways?
- Mazdutide
- Dual GIP/GLP-1 agonist
- 42% at 6mg weekly dose (highest studied)
- 6.8% at 6mg (Phase 2 data)
- Dual receptor activation produces stronger metabolic effect but compounds GI side effects during titration
- Moderate tolerability—requires structured dose escalation and dietary modification during weeks 0–12
- Semaglutide
- GLP-1 agonist only
- 44% at 2.4mg weekly (STEP trials)
- 7.0% at 2.4mg
- Single-receptor mechanism slightly simpler side-effect profile but similar GI symptom rates
- Comparable tolerability to mazdutide—GI effects driven primarily by GLP-1 component both compounds share
- Tirzepatide
- 33% at 15mg weekly (SURMOUNT trials)
- 6.2% at 15mg
- Similar dual mechanism to mazdutide but different molecular structure and dosing intervals
- Slightly better-tolerated in head-to-head comparison, likely due to optimized GIP:GLP-1 receptor affinity ratio
- Liraglutide
- GLP-1 agonist, daily dosing
- 39% at 3.0mg daily
- 9.9% at 3.0mg
- Daily injection burden and shorter half-life create different tolerance pattern—more frequent mild nausea versus weekly intense episodes
- Higher discontinuation rate suggests daily dosing may be less tolerable than weekly despite similar symptom frequency
- Survodutide
- Dual glucagon/GLP-1 agonist
- 51% at highest dose (Phase 2)
- 11.4% at highest dose
- Addition of glucagon receptor agonism amplifies metabolic effect but significantly worsens GI tolerability—nausea rates highest among dual agonists
- Poorest tolerability profile of dual-mechanism compounds—reserved for research contexts where maximum metabolic intervention outweighs side-effect burden